Search alternatives:
marked decrease » marked increase (Expand Search)
small decrease » small increased (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
marked decrease » marked increase (Expand Search)
small decrease » small increased (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
-
2
-
3
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
4
-
5
Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation.
Published 2024“…Colors indicate samples from different animals. Large circles show mean of cells from 5 fields of view from a single animal. …”
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration.
Published 2024“…Serum samples after bevacizumab treatment with an additional 2, 20, or 200 μg/mL of bevacizumab were compared to control samples without bevacizumab, indicating that free VEGF-A121 remained even at high doses of bevacizumab addition. …”
-
15
-
16
-
17
-
18
-
19
-
20